Products

Tafnat Tablet: The Next-Gen Tenofovir Alafenamide (TAF) for Chronic Hepatitis B – Global Supply by Ernest Oncology In the current landscape of antiviral therapy, Tafnat represents the pinnacle of safety and efficacy for patients battling Chronic Hepatitis B (HBV). Containing Tenofovir Alafenamide (25mg), Tafnat is a targeted nucleotide reverse transcriptase inhibitor (NtRTI) that delivers potent viral suppression while significantly reducing the risk of long-term kidney and bone density issues. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Tafnat to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Tafnat? (The TAF Advantage) Tafnat is a high-quality pharmaceutical version of the reference medication Vemlidy. It contains Tenofovir Alafenamide (25mg), which is a prodrug of Tenofovir. The primary advantage of Tafnat over older Tenofovir formulations (like TDF 300mg) is its targeted delivery system. Tafnat is more stable in the plasma, allowing it to enter the liver cells more efficiently. This means a much smaller dose (25mg) can achieve the same—or better—antiviral results with 90% less drug circulating in the bloodstream, protecting the patient's vital organs. Primary Indications & Medical Uses Chronic Hepatitis B (HBV): Treatment of chronic HBV infection in adults and adolescents with compensated liver disease. Renal & Bone Safety: The preferred choice for patients with a history of renal impairment or low bone mineral density. Undetectable Viral Load: Specifically designed to achieve and maintain undetectable HBV DNA levels. High Resistance Barrier: Demonstrated high efficacy with a very low risk of the virus developing resistance over long-term use. Detailed Product Information: Tafnat (25mg) Feature,Technical Specification Active Ingredient,Tenofovir Alafenamide (25mg) Therapeutic Class,Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturer,Natco Pharma Ltd. (India) Form,Film-coated tablets (30 Tablets per bottle) Dosage,One tablet daily with food Efficacy,Superior Hepatotropic Delivery Quality Standard, GMP Certified Production Mechanism of Action: Intracellular Viral Inhibition Tafnat stops the Hepatitis B virus from replicating by inhibiting the HBV polymerase: Selective Liver Uptake: The TAF molecule is designed to be absorbed primarily by hepatocytes (liver cells). Chain Termination: Once inside the cell, it is converted into Tenofovir diphosphate. This molecule incorporates itself into the viral DNA chain. Replication Block: It acts as a “stop“ signal, preventing the virus from completing its DNA sequence and effectively halting the infection. Dosage and Administration Standard Regimen: One 25mg tablet taken orally, once daily. Administration: Tafnat must be taken with food to ensure optimal absorption and consistent therapeutic levels. Patient Compliance: For maximum viral suppression, the dose should be taken at the same time every day. Storage: Store in a cool, dry place below 30°C in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Tafnat—manufactured by India's pharmaceutical giant Natco Pharma—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hepbest Tablet: The Gold Standard in Tenofovir Alafenamide (TAF) Therapy – Global Supply by Ernest Oncology In the evolving landscape of Chronic Hepatitis B (HBV) treatment, Hepbest stands out as a revolutionary advancement. Containing Tenofovir Alafenamide (25mg), Hepbest is a targeted antiviral designed to provide maximum viral suppression with significantly improved safety parameters for the kidneys and bones compared to older formulations. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We provide secure, GMP-compliant international distribution of Hepbest to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Hepbest? (The Science of TAF) Hepbest is a high-quality pharmaceutical version of the reference medication Vemlidy. It contains Tenofovir Alafenamide (25mg), a nucleotide reverse transcriptase inhibitor (NtRTI). The “TAF“ technology in Hepbest allows the medicine to remain more stable in the blood. This stability means the drug can be delivered more efficiently directly to the liver cells (hepatocytes). Consequently, patients can take a much lower dose (25mg) than the older 300mg TDF tablets, resulting in 90% less systemic exposure and reduced risk of long-term side effects. Primary Indications & Medical Uses Chronic Hepatitis B (HBV): For the treatment of chronic HBV infection in adults and adolescents (aged 12 years and older) with compensated liver disease. High Barrier to Resistance: Designed for long-term use with a very low risk of the virus developing resistance to the treatment. Renal and Bone Safety: The preferred choice for aging patients or those with existing concerns regarding kidney function or bone mineral density. Viral Suppression: Highly effective at bringing HBV DNA levels to “undetectable“ status. Detailed Product Information: Hepbest (25mg) Feature,Technical Specification Active Ingredient,Tenofovir Alafenamide (25mg) Therapeutic Class,Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturer,Mylan (Viatris) / Natco Pharma (India) Form,Film-coated tablets (30 Tablets per bottle) Standard Regimen,One tablet daily with food Safety Advantage,Lower renal and bone toxicity Quality Standard,WHO-GMP Certified Production Mechanism of Action: Targetted Antiviral Defense Hepbest works by inhibiting the Hepatitis B virus polymerase, the enzyme the virus uses to replicate its DNA: Hepatotropic Delivery: The TAF prodrug specifically targets liver cells. DNA Chain Termination: Once inside the liver cell, it is converted into Tenofovir diphosphate. It acts as a fake building block that the virus tries to use to build its DNA chain. Replication Blockade: Once incorporated, it stops the DNA chain from growing, effectively killing the virus's ability to reproduce. Dosage and Administration Dose: One 25mg tablet once daily. Administration: Hepbest must be taken with food to ensure proper absorption and consistent blood levels. Monitoring: Regular monitoring of liver function and HBV DNA levels is recommended to ensure the treatment is working effectively. Storage: Store in a cool, dry place below 30°C in the original moisture-proof bottle. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Hepbest—manufactured in India’s world-class facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for specialized pharmacy networks and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Durataf Tablet: The Next-Generation HBV Antiviral for Superior Liver Care – Global Supply by Ernest Oncology The medical management of Chronic Hepatitis B (HBV) has seen a significant breakthrough with the development of Tenofovir Alafenamide (TAF). Durataf, containing TAF 25mg, is a modern nucleotide reverse transcriptase inhibitor (NtRTI). It is designed to provide high-potency viral suppression while significantly improving the safety profile for the patient's kidneys and bone mineral density compared to older treatments. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Durataf to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Durataf? (The TAF Advantage) Durataf is a high-quality pharmaceutical version of the reference medication Vemlidy. It contains Tenofovir Alafenamide (25mg), a targeted prodrug of Tenofovir. Unlike the traditional Tenofovir Disoproxil Fumarate (TDF), Durataf is more stable in the bloodstream, allowing it to deliver the active drug more efficiently directly to the liver cells. This targeted delivery allows for a much lower dose (25mg vs. 300mg), resulting in 90% less Tenofovir in the systemic circulation, which minimizes the risk of renal and bone toxicity. Primary Indications & Medical Uses Chronic Hepatitis B (HBV): Indicated for the treatment of chronic HBV infection in adults and adolescents with compensated liver disease. HBeAg-Positive & HBeAg-Negative Patients: Highly effective across all stages of chronic infection and various viral profiles. Renal & Bone Safety: The preferred choice for long-term therapy, especially for patients with a history of kidney issues or osteoporosis. Viral Load Suppression: Specifically engineered to achieve and maintain undetectable HBV DNA levels. Detailed Product Information: Durataf (25mg) Feature Technical Specification Active Ingredient Tenofovir Alafenamide (25mg) Therapeutic Class Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturer Hetero Healthcare (India) Form Film-coated tablets (30 Tablets per pack) Treatment Cycle Long-term antiviral suppression Efficacy Rate High barrier to resistance Quality Standard GMP Certified Manufacturing Mechanism of Action: Targetted Viral Blockade Durataf works by inhibiting the Hepatitis B virus polymerase, effectively stopping the virus from replicating its genetic material: Selective Uptake: The TAF molecule is absorbed by the liver more effectively than previous generations of Tenofovir. DNA Chain Termination: Once inside the hepatocyte, it is converted into Tenofovir diphosphate. This molecule incorporates itself into the viral DNA, acting as a “roadblock“ that stops the DNA chain from growing, thereby killing the replication process. Dosage and Administration Standard Regimen: One 25mg tablet taken orally, once daily. Administration: Durataf should be taken with food to ensure optimal absorption. Consistency: For maximum viral suppression, the medication must be taken at the same time every day. Storage: Store in a cool, dry place below 30°C in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Durataf reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Tefowell AF 25mg Tablet: The Advanced HBV Treatment for Liver Health – Global Supply by Ernest Oncology The management of Chronic Hepatitis B Virus (HBV) has been fundamentally improved with the introduction of Tenofovir Alafenamide (TAF). Tefowell AF 25mg represents the latest generation of nucleotide reverse transcriptase inhibitors, designed to provide potent viral suppression while prioritizing the long-term safety of the patient's kidneys and bone mineral density. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Tefowell AF 25mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Tefowell AF 25mg? (The TAF Revolution) Tefowell AF 25mg is a high-quality pharmaceutical version of the reference medication Vemlidy. It contains Tenofovir Alafenamide (25mg), a targeted prodrug of Tenofovir. Unlike the older Tenofovir Disoproxil Fumarate (TDF), TAF is more stable in the plasma and delivers the active medicine more efficiently directly to the liver cells (hepatocytes). This allows for a much lower dose (25mg vs. 300mg), resulting in 90% less Tenofovir in the bloodstream and significantly reducing systemic side effects. Primary Indications & Medical Uses Chronic Hepatitis B (HBV): For the treatment of chronic HBV infection in adults and adolescents with compensated liver disease. HBeAg-Positive & HBeAg-Negative Patients: Proven efficacy across all stages of chronic infection. Renal & Bone Safety: The preferred choice for patients with existing kidney concerns or those at risk of osteoporosis. Viral Load Suppression: Designed for long-term daily use to maintain undetectable HBV DNA levels. Detailed Product Information: Tefowell AF (25mg) Feature Technical Specification Active Ingredient Tenofovir Alafenamide (25mg) Therapeutic Class Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturer Biocon / Leading Indian Pharma MNCs Form Film-coated tablets (30 Tablets per bottle) Treatment Type Long-term Antiviral Suppression Key Advantage Superior Renal & Bone Safety Profile Quality Standard GMP Certified Production Mechanism of Action: Intracellular Viral Inhibition Tefowell AF works by stopping the Hepatitis B virus from replicating its genetic material: Targeted Delivery: The TAF prodrug enters the liver cells more effectively than older versions of Tenofovir. Chain Termination: Once inside the cell, it is converted into Tenofovir diphosphate, which mimics the natural building blocks of viral DNA. It incorporates itself into the viral DNA chain, causing immediate termination of the replication process. Dosage and Administration Standard Regimen: One 25mg tablet taken orally, once daily. Administration: It is recommended to take Tefowell AF with food to ensure consistent absorption. Consistency: For maximum viral suppression, the dose must be taken at the same time every day. Storage: Store in a cool, dry place below 30°C in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Tefowell AF 25mg reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy requirements. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

X-Vir 0.5mg Tablet: The Potent Antiviral for Chronic Hepatitis B Suppression – Global Supply by Ernest Oncology In the landscape of Chronic Hepatitis B (HBV) therapy, maintaining a low viral load is essential to preventing long-term liver complications. X-Vir 0.5mg, containing the active ingredient Entecavir, is a world-class nucleoside analog (NA) designed for maximum viral suppression with a high genetic barrier to resistance. It is a gold-standard treatment for both treatment-naive and experienced patients. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of X-Vir 0.5mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is X-Vir 0.5mg? (The Entecavir Advantage) X-Vir 0.5mg is a high-quality generic version of Baraclude, manufactured by Natco Pharma, one of India's most respected pharmaceutical giants. Entecavir (0.5mg) is a guanosine nucleoside analog that selectively inhibits the Hepatitis B virus polymerase. It is favored by hepatologists globally because it offers faster viral clearance and a significantly lower risk of resistance compared to older therapies like Lamivudine or Adefovir. Primary Indications & Medical Uses Chronic Hepatitis B (HBV): For the treatment of chronic HBV infection in adults with evidence of active viral replication and persistent elevations in liver enzymes (ALT/AST). Compensated Liver Disease: Effective for managing patients with early-stage liver scarring to halt the progression toward cirrhosis. HBeAg-Positive & HBeAg-Negative Patients: Proven efficacy across various viral profiles and clinical stages of chronic infection. Nucleoside-Naive Patients: The preferred first-line therapy for patients who have not previously taken antiviral medications for HBV. Detailed Product Information: X-Vir (0.5mg) Feature Technical Specification Active Ingredient Entecavir (0.5mg) Therapeutic Class Nucleoside Reverse Transcriptase Inhibitor (NRTI) Manufacturer Natco Pharma Ltd. (India) Form Film-coated tablets (30 Tablets per bottle) Treatment Type Long-term antiviral suppression Resistance Profile High genetic barrier ( <1% resistance in 5 years) Quality Standard GMP & ISO Certified Production Mechanism of Action: Triple-Stage Inhibition X-Vir works by inhibiting the Hepatitis B virus polymerase at three distinct stages of its lifecycle: Base Priming: It prevents the initial attachment of the viral DNA. Reverse Transcription: It blocks the formation of the negative strand of the DNA from the pregenomic RNA. DNA Synthesis: It halts the synthesis of the positive strand of the viral DNA. Dosage and Administration Standard Regimen: One 0.5mg tablet taken orally, once daily. Empty Stomach Rule: For optimal absorption, X-Vir must be taken on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). Long-term Compliance: Chronic HBV is a long-term condition; patients must take the medication at the same time every day to ensure continuous viral suppression. Storage: Store at room temperature (below 30°C) in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that X-Vir 0.5mg reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ access programs in London and across the UK. United States: Providing cost-effective supply for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health initiatives, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Entaliv 0.5mg Tablet: The Potent Antiviral for Chronic Hepatitis B Management – Global Supply by Ernest Oncology The long-term management of Chronic Hepatitis B (CHB) requires high-potency antiviral therapy with a high barrier to resistance. Entaliv 0.5mg, containing the active ingredient Entecavir, is a primary first-line therapy recognized globally for its ability to suppress viral replication, normalize liver enzymes, and prevent the progression of liver cirrhosis and hepatocellular carcinoma. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Entaliv 0.5mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Entaliv 0.5mg? (The Entecavir Advantage) Entaliv 0.5mg is a high-quality pharmaceutical version of the reference medication Baraclude. Entecavir is a guanosine nucleoside analog with selective activity against the Hepatitis B virus (HBV) polymerase. It is favored by hepatologists worldwide because it is significantly more potent than older generation antivirals and maintains a remarkably low rate of resistance in treatment-naive patients. Primary Indications & Medical Uses Chronic Hepatitis B (CHB): Indicated for the treatment of chronic HBV infection in adults with evidence of active viral replication. Compensated Liver Disease: Used to manage patients with persistent elevations in serum aminotransferases (ALT or AST) and histological evidence of active disease. HBeAg-Positive & HBeAg-Negative Patients: Highly effective across different viral profiles and stages of chronic infection. Long-term Suppression: Specifically designed for daily use to keep viral loads at undetectable levels and promote liver health. Detailed Product Information: Entaliv (0.5mg) Feature Technical Specification Active Ingredient Entecavir (0.5mg) Therapeutic Class Nucleoside Analog Reverse Transcriptase Inhibitor Manufacturer Dr. Reddy's Laboratories / Leading Indian MNCs Form Film-coated tablets (10/30 Tablets per pack) Treatment Type Long-term Viral Suppression Resistance Profile High Genetic Barrier to Resistance Quality Standard GMP & ISO Certified Manufacturing Mechanism of Action: Triple-Stage Viral Blockade Entaliv 0.5mg stops the Hepatitis B virus from reproducing by inhibiting the HBV polymerase through three distinct functional steps: Base Priming: It prevents the initial attachment of the viral DNA. Reverse Transcription: It blocks the formation of the negative strand of the DNA from the pregenomic RNA. DNA Synthesis: It halts the synthesis of the positive strand of the viral DNA. Dosage and Administration Standard Regimen: One 0.5mg tablet taken orally, once daily. Empty Stomach Requirement: For maximum bioavailability, Entaliv must be taken on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). Consistency: Patients must take the medication at the same time every day to maintain steady-state plasma concentrations. Storage: Store in a cool, dry place below 30°C in the original moisture-proof packaging. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Entaliv 0.5mg—manufactured by India's pharmaceutical giant Dr. Reddy's—reaches our global partners through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Entavir 0.5mg Tablet: The Advanced Antiviral Solution for Chronic Hepatitis B – Global Supply by Ernest Oncology The long-term management of Chronic Hepatitis B (CHB) has been revolutionized by potent nucleoside analogs that offer a high barrier to viral resistance. Entavir 0.5mg, containing the active ingredient Entecavir, is a primary first-line therapy recognized globally for its ability to suppress viral replication, normalize liver enzymes, and prevent the progression of liver cirrhosis and hepatocellular carcinoma. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Entavir 0.5mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Entavir 0.5mg? (The Entecavir Advantage) Entavir 0.5mg is a high-quality generic version of the reference medication Baraclude. Entecavir is a guanosine nucleoside analog with selective activity against the Hepatitis B virus (HBV) polymerase. It is favored by hepatologists worldwide because it is significantly more potent than older generation antivirals like Lamivudine and maintains a remarkably low rate of resistance in treatment-naive patients. Primary Indications & Medical Uses Chronic Hepatitis B (CHB): Indicated for the treatment of chronic HBV infection in adults with evidence of active viral replication. Compensated Liver Disease: Used to manage patients with persistent elevations in serum aminotransferases (ALT or AST) and histological evidence of active disease. HBeAg-Positive & HBeAg-Negative Patients: Highly effective across different viral profiles and stages of chronic infection. Prevention of Disease Progression: Long-term use significantly reduces the risk of liver failure and the eventual need for liver transplantation. Detailed Product Information: Entavir (0.5mg) Feature Technical Specification Active Ingredient Entecavir (0.5mg) Therapeutic Class Nucleoside Analog Reverse Transcriptase Inhibitor Manufacturer Cipla Ltd. (India) Form Film-coated tablets (10/30 Tablets per pack) Treatment Type Long-term Viral Suppression Resistance Profile Extremely high barrier to resistance Quality Standard GMP & ISO Certified Manufacturing Mechanism of Action: Triple-Stage Viral Blockade Entavir 0.5mg stops the Hepatitis B virus from reproducing by inhibiting the HBV polymerase through three distinct functional steps: Base Priming: It prevents the initial attachment of the viral DNA. Reverse Transcription: It blocks the formation of the negative strand of the DNA from the pregenomic RNA. DNA Synthesis: It halts the synthesis of the positive strand of the viral DNA. Dosage and Administration Standard Regimen: One 0.5mg tablet taken orally, once daily. Empty Stomach Requirement: For maximum bioavailability, Entavir must be taken on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). Consistency: Patients must take the medication at the same time every day to maintain steady-state plasma concentrations. Storage: Store in a cool, dry place below 30°C in the original moisture-proof packaging. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Entavir 0.5mg—manufactured by India's pharmaceutical giant Cipla—reaches our global partners through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Entewell 0.5mg Tablet: The Gold Standard for Chronic Hepatitis B Suppression – Global Supply by Ernest Oncology The long-term management of Chronic Hepatitis B (HBV) requires high-potency antiviral therapy with a high barrier to resistance. Entewell 0.5mg, containing the active ingredient Entecavir, is one of the most widely prescribed Nucleoside Analogs (NAs) globally. Designed for superior viral suppression, Entewell is a cornerstone in preventing the progression of liver disease, including cirrhosis and hepatocellular carcinoma. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Entewell 0.5mg to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Entewell 0.5mg? (The Entecavir Advantage) Entewell 0.5mg is a premium generic version of the world-renowned medication Baraclude. Entecavir is a potent guanosine nucleoside analog that selectively inhibits the Hepatitis B virus polymerase. Clinical data consistently shows that Entecavir is more effective than older treatments like Lamivudine, offering faster viral load reduction and a negligible rate of resistance in treatment-naive patients. Primary Indications & Medical Uses Chronic Hepatitis B Virus (HBV): For the treatment of chronic HBV infection in adults with evidence of active viral replication and persistent elevations in serum aminotransferases (ALT or AST). Compensated Liver Disease: Effective for patients with early-stage liver scarring to prevent further damage. HBeAg-Positive & HBeAg-Negative Patients: Proven efficacy across various viral profiles and stages of chronic infection. Nucleoside-Naive Patients: The preferred first-line therapy for patients who have not previously taken antiviral medications for HBV. Detailed Product Information: Entewell (0.5mg) Feature Technical Specification Active Ingredient Entecavir (0.5mg) Therapeutic Class Nucleoside Reverse Transcriptase Inhibitor (NRTI) Manufacturer Biocon / Natco Pharma (India) Form Film-coated tablets (30 Tablets per bottle) Treatment Type Long-term antiviral suppression Safety Profile High barrier to viral resistance Quality Standard GMP Certified Production Mechanism of Action: Triple-Stage Inhibition Entewell works by inhibiting the Hepatitis B virus polymerase at three distinct stages of its lifecycle: Base Priming: It prevents the initial attachment of the viral DNA. Reverse Transcription: It blocks the formation of the negative strand of the DNA from the pregenomic RNA. Dosage and Administration Standard Regimen: One 0.5mg tablet taken orally, once daily. Empty Stomach Rule: For optimal absorption, Entewell must be taken on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal). Monitoring: Patients should undergo regular blood tests to monitor HBV DNA levels and liver enzymes to ensure treatment success. DNA Synthesis: It halts the synthesis of the positive strand of the viral DNA. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the logistics of international pharmaceutical trade. We ensure that Entewell 0.5mg—manufactured in India’s leading biotech facilities—reaches our global partners through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ programs in London and nationwide. United States: Providing affordable access for clinical research, specialized pharmacy requirements, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Mydekla Tablet: The Potent NS5A Inhibitor for Hepatitis C Eradication – Global Supply by Ernest Oncology The treatment of Chronic Hepatitis C (HCV) has been fundamentally transformed by the advent of Direct-Acting Antivirals (DAAs). Mydekla, containing Daclatasvir (60mg), is a cornerstone of this modern therapeutic approach. As a powerful NS5A inhibitor, Mydekla is designed to be used in combination with other antivirals to achieve high cure rates across multiple genotypes of the virus, offering a reliable path to viral clearance with an all-oral regimen. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, GMP-compliant international distribution of Mydekla to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Mydekla? (The Power of Daclatasvir) Mydekla is a high-quality generic version of the breakthrough medication Daklinza. It targets the Hepatitis C virus by inhibiting a specific protein the virus needs to replicate. When Mydekla is paired with a nucleotide analog like Sofosbuvir, it creates a robust antiviral shield that works effectively even in patients who have not responded to previous interferon-based treatments. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Extensively used in combination with Sofosbuvir for these prevalent genotypes. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its minimal drug-drug interactions. Advanced Liver Disease: A vital treatment component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Effective in managing HCV recurrence in liver transplant recipients. Detailed Product Information: Mydekla (60mg) Feature, Technical Specification Active Ingredient Daclatasvir (60mg) Therapeutic Class HCV NS5A Replication Complex Inhibitor Manufacturer Mylan (Viatris) / Natco Pharma (India) Form Film-coated tablets (28 Tablets per bottle) Treatment Cycle 12 to 24 Weeks (depending on regimen) Efficacy Rate >90% Sustained Virologic Response (SVR) Quality Standard GMP Certified Production Mechanism of Action: Blocking Viral Assembly Mydekla works by interfering with the most critical stage of the virus's lifecycle: Inhibiting NS5A Protein: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for the replication of the viral RNA and the subsequent assembly of new virus particles. Halting the Viral Cycle: By blocking this protein, Mydekla ensures that the virus cannot reproduce or spread to healthy liver cells, allowing the body to clear the infection permanently. Dosage and Administration Standard Regimen: One 60mg tablet taken once daily. Combination Requirement: Mydekla must be taken in combination with other antiviral medicines (typically Sofosbuvir 400mg). Administration: Can be taken with or without food. It is essential to take the dose at the same time every day for maximum efficacy. Storage: Store in a cool, dry place below 30°C in the original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Mydekla—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs throughout the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep Tablet: The Gold Standard in Chronic Hepatitis C Treatment – Global Supply by Ernest Oncology The medical landscape for Chronic Hepatitis C (HCV) was forever changed with the introduction of Direct-Acting Antivirals (DAAs). Myhep, featuring the breakthrough active ingredient Sofosbuvir (400mg), remains the foundation of most successful HCV treatment regimens. As a potent nucleotide analog polymerase inhibitor, Myhep is designed to stop the virus at its source, offering a pathway to a permanent cure for millions worldwide. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Myhep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Myhep? (The Sofosbuvir Breakthrough) Myhep is a high-quality generic version of the world-renowned medication Sovaldi. It contains Sofosbuvir (400mg), which was the first drug to offer high cure rates with a simplified oral regimen. Before Sofosbuvir, treatment often involved grueling interferon injections with low success rates; Myhep has replaced that era with an effective, all-oral solution. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, & 4): Myhep is a versatile “backbone“ drug, usually used in combination with other antivirals (like Daclatasvir or Ledipasvir) to treat various HCV genotypes. HCV/HIV Co-infection: Proven safe for patients managing both conditions, maintaining a stable drug-interaction profile. Liver Transplant Candidates: Often used to prevent the recurrence of Hepatitis C in patients awaiting or recovering from a liver transplant. Detailed Product Information: Myhep (400mg) Feature, Technical Specification Active Ingredient, Sofosbuvir (400mg) Therapeutic Class Nucleotide Analog HCV NS5B Polymerase Inhibitor Manufacturer Mylan (Viatris) / Natco Pharma (India) Form, Film-coated tablets (28 Tablets per bottle) Standard Duration 12 to 24 Weeks (based on combination) Efficacy Rate >90% Sustained Virologic Response (SVR) Quality Standard GMP Certified Production Mechanism of Action: Chain Termination Myhep works by targeting the heart of the virus's replication machinery: NS5B Protein Inhibition: Sofosbuvir is a prodrug that, once inside the liver, converts into an active triphosphate. Stopping Replication: It mimics the natural building blocks of the virus's RNA. When the virus tries to use Myhep to build its genetic chain, the chain is “terminated,“ effectively stopping the virus from reproducing. Dosage and Administration Standard Regimen: One 400mg tablet taken once daily. Combination Therapy: Myhep is rarely used alone; it is typically taken with Ribavirin or another DAA (like Myhep DV). Administration: Can be taken with or without food. It is vital to take the tablet at the same time every day to ensure consistent antiviral levels. Storage: Store at room temperature (below 30°C) in its original moisture-proof container. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Myhep—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Daclahep Tablet: The Potent NS5A Inhibitor for Hepatitis C Cure – Global Supply by Ernest Oncology The evolution of Direct-Acting Antivirals (DAAs) has made Hepatitis C (HCV) a highly curable condition. Daclahep, containing Daclatasvir (60mg), is a cornerstone of modern HCV therapy. When used in combination with other antivirals like Sofosbuvir, it provides a robust, all-oral treatment pathway that targets the virus across multiple genotypes, ensuring high Sustained Virologic Response (SVR) rates. Ernest Oncology, the premier pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We specialize in the secure, GMP-certified international distribution of Daclahep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa. What is Daclahep? Daclahep is a high-quality generic version of the breakthrough medication Daklinza. As a powerful NS5A inhibitor, it prevents the Hepatitis C virus from replicating and assembling new viral particles. Because it is rarely used alone, it is most commonly paired with Sofosbuvir to create a pan-genotypic treatment regimen that eliminates the need for interferon injections. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Particularly effective when combined with Sofosbuvir for these prevalent genotypes. Advanced Liver Disease: A vital component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Used in specialized regimens to prevent HCV recurrence after transplantation. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its favorable drug-interaction profile. Detailed Product Information: Daclahep (60mg) Feature, Technical Specification Active Ingredient: Daclatasvir (60mg) Drug Class: NS5A Replication Complex Inhibitor Manufacturer: Hetero Healthcare / Natco Pharma (India) Form film-coated tablets (28 Tablets per pack) Standard Regimen, 12 to 24 Weeks (based on clinical profile) Quality Standard, GMP Certified Manufacturing Mechanism of Action: Disrupting Viral Assembly Daclahep works by targeting a specific protein within the Hepatitis C virus: NS5A Protein Inhibition: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for both the replication of the viral RNA and the assembly of the new virus particles (virions). Viral Clearance: By blocking this protein, the medication stops the virus from spreading to new liver cells, allowing the body’s immune system and companion antivirals to clear the infection. Dosage and Administration Standard Dose: One 60mg tablet taken orally, once daily. Combination Therapy: Must be taken with Sofosbuvir (400mg) or as directed by a hepatologist. Administration: Can be taken with or without food. Consistency is vital—doses should be taken at the same time every day. Storage: Store in a cool, dry place below 30°C, protected from light and moisture. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Daclahep—manufactured by India's leading pharmaceutical giants—is delivered through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hepcinat Plus Tablet: The Advanced Dual-Action Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of Direct-Acting Antiviral (DAA) combinations has revolutionized the treatment of Chronic Hepatitis C, turning a once-chronic condition into a curable one. Hepcinat Plus, a potent fixed-dose combination of Sofosbuvir (400mg) and Daclatasvir (60mg), stands at the forefront of this medical breakthrough. This combination is highly effective across multiple genotypes and is widely prescribed for its high cure rates and manageable side-effect profile. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Hepcinat Plus to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Hepcinat Plus? Hepcinat Plus is a high-quality generic version of the combination therapy used to treat Chronic Hepatitis C. By combining two distinct antiviral mechanisms, Hepcinat Plus eliminates the need for interferon injections, which were previously the standard of care but carried significant side effects. Clinical data indicates a Sustained Virologic Response (SVR12)—the clinical definition of a cure—in over 95% of treated patients. Primary Indications & Medical Uses Chronic Hepatitis C (Multiple Genotypes): Specifically effective for Genotypes 1, 3, and 4, providing a robust treatment path for a wide range of patients. HCV/HIV Co-infection: Safe for use in patients managing both Hepatitis C and HIV-1, with a well-documented drug-interaction profile. Patients with Cirrhosis: Effective for patients with compensated liver disease, often used to prevent further liver damage and the need for transplantation. Detailed Product Information: Hepcinat Plus (400mg/60mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Daclatasvir (60mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration, Standard 12-Week Course Success Rate: >95% Sustained Virologic Response (SVR) Quality Standard, GMP Certified Production Mechanism of Action: The Dual-Inhibitor Strategy Hepcinat Plus works by attacking the Hepatitis C virus at two critical stages of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Daclatasvir (60mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication of the virus and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily. Administration: Can be taken with or without food. Consistency is critical; the dose should be taken at the same time every day to maintain optimal antiviral levels in the blood. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Hepcinat Plus—manufactured by Natco Pharma—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383